PhoreMost, a UK-based biopharmaceutical company dedicated to developing drugs against intractable disease targets, and Polaris Quantum Biotech, a North Carolina-based quantum computing drug design company, will collaborate to study oncology targets currently considered undruggable.
Metrion Biosciences, a specialist ion channel contract research and drug discovery company, and Bioqube Ventures, a specialist European life sciences investment firm, have entered into a collaboration, backed by Bioqube Factory Fund I, to incubate a drug discovery research project targeting autoimmune diseases.
MolGen B.V., a provider of DNA / RNA extraction technology, has opened an office in London, UK. The new location will serve as a pivotal branch to provide laboratories in the UK with access to the company’s extraction DNA / RNA portfolio across diagnostics, pharma and the biotech industry. The opening of the London office […]
42 Technology (42T), FIND, the global alliance for diagnostics, and Rutgers University have worked together to develop an innovative stool sample processing kit that has played a central role in informing the World Health Organi-zation’s (WHO) recent policy update to improve the diagnosis of tuberculosis (TB) in children.
Insightful Science, a software company enabling the Cloud for Scientific Discovery, has acquired Protein Metrics, a leading provider of biopharmaceutical protein characterization and proteomics analysis software. The acquisition expands the company’s R&D value chain to widen the biopharmaceutical protein analysis arena, unblocking data analysis bottlenecks currently associated with large-scale protein studies.
GenNext Technologies, a growth-stage company providing instrumentation, software, and services, has earned a second patent protecting the company’s novel radical dosimetry technology which vastly improves the utility of protein footprinting for the study of biopharma-ceutical structure, function, and safety.
EKF Diagnostics, the global in vitro diagnostics company, has acquired Advanced Diagnostic Laboratory (“ADL Health”), a Texas based PCR-focused testing laboratory certified under the Clinical Laboratory Improvement Amendments (“CLIA”) for high-complexity molecular diagnostics testing. ADL Health’s CLIA-certified laboratory covers the fields of clinical, forensic and microbiological tests. The business has ISO 15189 Medical Laboratory accreditation […]
A collaboration between Cytel and Pulse Infoframe will support rare disease drug development sponsors seeking real-world evidence where the data generated can be used for a range of purposes, from synthetic controls and comparative effectiveness to pricing reimbursement. Cytel, a leader in the field of advanced analytics for life sciences, has spent the past 30 […]
AMSBIO has expanded its range of custom gene editing services to complement its extensive portfolio of off-the-shelf CRISPR/Cas9 products. AMSBIO CRISPR/Cas9 products are widely used by research groups worldwide in applications including gene mutation studies, epigenetic editing, cell and embryo therapies, and genomic-scale screening.
SOTIO Biotech, a clinical stage immuno-oncology company owned by PPF Group, announced an exclusive, target-specific license and option agreement with LegoChem Biosciences, a biotechnology company focused on developing its clinical-stage platform technology enabling antibody-drug conjugates (ADCs) with an excellent therapeutic index. SOTIO will obtain rights to deploy LCB’s ADC technology for up to five therapeutic programs targeting distinct tumour-associated antigens.
The deal enables SOTIO to combine its proprietary antibodies with LCB’s ADC technology platform in order to deliver novel therapeutics for the treatment of solid tumours and includes LCB’s proprietary conjugation technology ‘ConjuAll’ and potent linker-payload platform including multiple different payloads.
Under the terms of the multi-target agreement, LCB is eligible to receive upfront and potential milestone payments worth up to $1027.5 million, payable based on certain developments and regulatory achievements, plus royalties on net sales. The deal includes upfront and near-term milestones worth up to $29.5 million, subject to exercise of the options and achievement of success-based milestones. No further financial details were disclosed.
“At SOTIO we are building an innovative pipeline of ADC programs and plan IND filing for our lead program SOT102 by the end of 2021. The licensing agreement with our new, experienced partner LegoChem allows us to broaden our oncology pipeline with additional programs and solid tumour targets. We are looking forward to using the potential of LegoChem’s ADC technology platform and to develop innovative ADCs for patients in need,” said Radek Spisek, M.D., Ph.D., chief executive officer of SOTIO.
SOTIO will be responsible for research, development, manufacturing and commercialization of the ADC products, while LCB will support and work closely with SOTIO for the research activities and the manufacturing of components that are specifically related to its proprietary ConjuAll and the linker-payload technologies.
Dr. Yong-Zu Kim, CEO and President of LCB added: “This collaboration is yet another example that illustrates how the value proposition of the LCB platform can increase the competitive position of our partners within the ADC space. SOTIO is an ideal partner for LCB due to its expertise and strategic focus on innovative antibody drug conjugates, and we look forward to working closely together on multiple innovative programs.”
November 2025
Prins Hendrikstraat 1
5611HH Eindhoven
The Netherlands
info@clinlabint.com
PanGlobal Media is not responsible for any error or omission that might occur in the electronic display of product or company data.